Printer Friendly
The Free Library
14,679,288 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Oscient Pharmaceuticals to Present at Fourth Annual JMP Securities Research Conference; Webcast of Presentation Available Wednesday, March 2, 2005 at 8:50 AM PT.


WALTHAM, Mass. -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) will participate in the Fourth Annual JMP JMP Jump
JMP Java Memory Profiler
JMP Joint Manpower Program
JMP Joint Management Plan
JMP Joint Marketing Program
JMP JCL Manipulation Program
JMP Joint Mission Planning (US DoD)
JMP Joint Military Program
 Securities Research Conference on March 2, 2005 in San Francisco. The Company's President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE Fac´tive

a. 1. Making; having power to make.
 (R) (gemifloxacin mesylate) tablets, the Company's lead product. The presentation will begin at 8:50 AM PT (11:50 AM ET) on Wednesday and will be webcast through the Company's website at www.oscient.com. An archive of the webcast will also be available for 90 days.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a biopharmaceutical company committed to the clinical development and commercialization of novel therapeutics to address unmet medical needs. The Company is marketing FACTIVE (R) (gemifloxacin mesylate) tablets, approved by the FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. In addition to the oral tablet form, Oscient Pharmaceuticals is developing an investigational FACTIVE intravenous formulation for hospitalized patients.

The Company has a novel antibiotic candidate, Ramoplanin, in advanced clinical development for the treatment of Clostridium clostridium

Any of the rod-shaped, usually gram-positive bacteria (see gram stain) that make up the genus Clostridium. They are found in soil, water, and the intestinal tracts of humans and other animals. Some species grow only in the complete absence of oxygen.
 difficile-associated diarrhea (CDAD CDAD Clostridium Difficile-Associated Diarrhea
CDAD Component Data Administrator
). The Company's preclinical program includes an oral peptide deformylase (PDF) inhibitor series, under preclinical development for community-based respiratory tract infections.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Feb 23, 2005
Words:211
Previous Article:Lions Petroleum, Inc.: Corporate Update.
Next Article:A.M. Best Affirms Rating of LG Insurance Company Limited.



Related Articles
ADVISORY/Transmeta Corporation to Present at the Third Annual JMP Securities Research Conference.
REMINDER/Transmeta Corporation to Present at the Third Annual JMP Securities Research Conference.
Delta Financial Corporation to Present at the Fourth Annual JMP Securities Research Conference.
Cubist Pharmaceuticals to Present at JMP Securities Fourth Annual Research Conference and Wells Fargo Securities Health Care Fireside Chats.
Cost Plus, Inc. to Present at the Fourth Annual JMP Securities Research Conference.
Incyte to Present at Several Upcoming Investor Conferences.
F5 Networks to Present at the JMP Securities Annual Research Conference.
Intersil Corporation to Present at JMP Securities Conference.
Oscient Pharmaceuticals to Present at Fifth Annual JMP Securities Research Conference.
Oscient Pharmaceuticals to Participate in the Sixth Annual JMP Securities Research Conference.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles